Purpose
The incidence of non-alcoholic fatty liver disease (NAFLD) has increased considerably over the last 10 years to become the first cause of chronic liver diseases in developed countries.Nonalcoholic steatohepatitis (NASH) is characterized in additition to steatosis by inflammation and hepatocyt injury leading to fibrosis.
It's important to make an early diagnosis because the major complications of this disease are lifethreateningand include portalhypertension,
liver insufficiency,and hepatocellular carcinoma.
Liver biopsy remains the gold standard for liver fat quantification as well as diagnosing and staging hepatic fibrosis.
Morbidity...
Methods and materials
Between September 2013 and June 2015,
55 patients (34 men and 21 women,
mean age: 50.6years,
range: 22-80) with chronic liver disease were prospectively screened by biopsy and liverMRI.
Acquisitions were performed on a 3.0T MR750(GEHC) system.
The protocol includeda set of routine sequences andinnovative MRI technics which were already exposed and validate by Leporq et al.
:
1) SPGR multi-angle,
multi-echo sequence to quantify fat volume fraction (FVF),
a method including an estimation and correction of relaxation time effects,
accounting for the NMR spectrum...
Results
We present in this preliminary study the results of 55 patients (Hepatomap cohort includes 106 patients in all):
MRI-based FVF values were very significantly correlated with histological steatosis rate(CorrS=0,917,
p<0,0001) Fig. 3.
AUC for steatosis was respectively 0,956 [IC 0,907-1]; 0,983 [IC0,958-1] and 0,954 [IC 0,892-1] for stage I(n=35),
II(n=20) and III(n=6).
Fig. 4 and Fig. 5.
MRI-based perfusionparameters were significantly correlated with fibrosis score (CorrS was 0,320 (p=0,021) for MTT,0,400 (p=0,003) for HPI,
and -0,291(p=0,036) for portal debit.
Fig. 6
None of the IVIM...
Conclusion
HEPATOMAP is the first large-scale prospective study to our knowledge that combines all these three advanced MRI technics to investigate fibrosis and fatty liver.
Personal information
Edouard Herriot Hospital
5 Place d’Arsonval,
69003 Lyon
References
1.Harrison SA,
Neuschwander-Tetri BA.
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Clin Liver Dis.
2004 Nov;8(4):861–79,
ix.
2.Ratziu V,
Bellentani S,
Cortez-Pinto H,
Day C,
Marchesini G.
A position statement on NAFLD/NASH based on the EASL 2009 special conference.
Journal of Hepatology.
2010 Aug;53(2):372–84.
3.Stamatakis E,
Primatesta P,
Chinn S,
Rona R,
Falascheti E.
Overweight and obesity trends from 1974 to 2003 in English children: what is the role of socioeconomic factors? Arch Dis Child.
2005 Oct;90(10):999–1004.
4.Wong RJ,
Aguilar M,
Cheung R,
Perumpail RB,...